When Bristol-Myers said its combination of Opdivo, Yervoy and chemo had topped solo chemo at lengthening lung cancer patients’ lives, analysts and investors wondered if the three-drug regimen had spurred a survival benefit on par with Merck’s market-leading Keytruda-chemo combo.
read moreJust days away from an FDA decision that could finally bring Bristol Myers Squibb’s Opdivo to previously untreated non-small cell lung cancer patients, the company’s Opdivo-Yervoy combo has put up positive three-year data. More: ASCO: Bristol Myers Squibb, awaiting Opdivo-Yervoy
read morePfizer and Astellas’ Xtandi is already approved to treat non-metastatic castration-resistant prostate cancer, thanks to data showing it can stop tumors from spreading. But now it’s adding results that show it can help patients live longer, too. More: ASCO: Pfizer,
read moreBack in January, Merck said Keytruda—its anti-PD-1 therapy—had missed the mark in small cell lung cancer, an area where two of its rivals had succeeded. Both those rivals are anti-PD-L1 treatments, so could that PD-1/PD-L1 difference be the reason? The
read moreRight now, Roche’s Tecentriq is the only drug in its class with an approval in previously untreated triple-negative breast cancer, a particularly aggressive form of the disease. But Merck & Co. is laying out its case to change that. More:
read moreThe move could help accelerate the development and review of the mRNA vaccine candidate More: Fast track for Moderna's novel coronavirus vaccine Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals